Wipro GE Healthcare has announced an investment of more than Rs80bn ($959m) in India, aimed at expanding its capabilities in medical device technology manufacturing.

The investment, which is planned over the next five years, will see an increase in the company’s manufacturing output and local research and development (R&D).

The move is expected to strengthen Wipro GE Healthcare's manufacturing capabilities to cater to the increasing demand from both domestic and international markets.

It also aims to fortify the company's supply chain resilience.

As part of this initiative, Wipro GE Healthcare plans to produce positron emission tomography (PET) computed tomography (CT) Discovery IQ diagnostic scan devices for exportation to 15 countries.

This aligns with the company's commitment to manufacturing 'In India for the World'.

Furthermore, aligning with the ‘Made in India’ programme, products such as the Revolution Aspire CT, Revolution ACT, and MR breast coils will be produced domestically for global distribution.

Wipro GE Healthcare currently operates four manufacturing plants in Bengaluru, Karnataka, India, all of which focus on exports.

Wipro GE Healthcare is a joint venture between India's Wipro Enterprises and a wholly owned entity of US-based GE Healthcare.

GE HealthCare president and CEO Peter J Arduini said: “India is a high potential, high priority market for GE HealthCare globally. In fact, we are among the first medtech companies to ‘Make in India – for India and the world’.

“We will continue to invest in expanding India’s domestic capabilities and its global footprint in medtech manufacturing and R&D. Today’s announcement is aligned with our strategic vision to deliver precision innovation globally and accelerate India’s position as medtech innovation and manufacturing hub for India and for world markets.”

Last year, GE HealthCare and Advantus Health Partners signed a multi-year agreement to expand access to healthcare technology management services.